Introduction The coronavirus (COVID-19) pandemic is placing unprecedented strain on healthcare services across the world ( 1 ), with the UK’s National Health Service (NHS) experiencing greatest challenge in 70 years of its existence ( 2 ). The
Search Results
Impact of COVID-19 on UK stress echocardiography practice: insights from the EVAREST sites
Cameron Dockerill, William Woodward, Annabelle McCourt, Cristiana Monteiro, Elena Benedetto, Maria Paton, David Oxborough, Shaun Robinson, Keith Pearce, Mark J Monaghan, Daniel X Augustine, and Paul Leeson
A minimum dataset for a Level 1 echocardiogram: a guideline protocol from the British Society of Echocardiography
Rakhee Hindocha, David Garry, Nadia Short, Tom E Ingram, Richard P Steeds, Claire L Colebourn, Keith Pearce, Vishal Sharma, and the Accreditation and Education Committees of the British Society of Echocardiography
, for example, when managing patients with highly contagious respiratory infections such as COVID-19. Level 1 echocardiography should be viewed as a separate test from a Level 2 echocardiogram, with clear indications and contraindications which are
British Society for Echocardiography and British Cardio-Oncology Society guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab
Rebecca Dobson, Arjun K Ghosh, Bonnie Ky, Tom Marwick, Martin Stout, Allan Harkness, Rick Steeds, Shaun Robinson, David Oxborough, David Adlam, Susannah Stanway, Bushra Rana, Thomas Ingram, Liam Ring, Stuart Rosen, Chris Plummer, Charlotte Manisty, Mark Harbinson, Vishal Sharma, Keith Pearce, Alexander R Lyon, Daniel X Augustine, and the British Society of Echocardiography (BSE) and the British Society of Cardio-Oncology (BCOS)
context of current pandemics (e.g. COVID-19) ( 17 , 18 ). Recommendations for echocardiography during and after anthracycline-containing chemotherapy also differ, with the majority of guidelines not quantifying the frequency of monitoring ( 19 , 20
